Oncoceutics announced that the Japanese Patent Office has issued Japanese Patent No. 6132833 for the use of ONC201 to treat all cancers or patients having a risk of cancer, including brain, colon, breast, colorectal cancers, and glioblastoma.
Philadelphia, PA (January 8, 2018) – Oncoceutics announced that the Japanese Patent Office (JPO) has issued Japanese Patent No. 6132833 for the use of ONC201 to treat all cancers or patients having a risk of cancer, including brain, colon, breast, colorectal cancers, and glioblastoma. The claims issued also include the use of ONC201 when administered in conjunction with another anticancer agent and 25 routes of administration, including oral administration.
This is the first patent issued outside the United States covering ONC201. This patent, combined with issued patents for ONC201 formulation and use in combination with other therapies, as well as FDA regulatory designations that ONC201 has received, provides ONC201 with a robust suite of intellectual property.
ONC201, a member of the imipridone family, has demonstrated anti-cancer activity and safety in preclinical models and ongoing clinical trials, including a trial for various solid and liquid tumors. Oncoceutics has also received patents covering its next generation of imipridones, namely ONC206 and ONC212.
“We are delighted that the Japanese Patent Office has recognized these indications as novel uses of ONC201 and granted these broad patent protections in such an important market,” said Martin Stogniew, Ph.D., Chief Development Officer of Oncoceutics. “The company’s current patent estate gives Oncoceutics more than 15 years of patent protection for the vast majority of human cancers, including tumor types where ONC201 is currently in Phase II trials.”
About Oncoceutics
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds that selectively target G protein-coupled receptors for oncology. The first lead compound to result from this program is ONC201, an orally active DRD2 small molecule antagonist that is well-tolerated and effective against advanced cancers. The company recently completed a successful Phase I study in solid tumors and has begun additional Phase I/II and Phase II clinical programs in both solid and hematological malignancies. Oncoceutics and collaborative groups have received significant grants over the last two years, from institutions such as the National Cancer Institute, the U.S. Food and Drug Administration, the Pennsylvania Department of Health, and The Musella Foundation. In addition, outside interest in the company’s portfolio has resulted in several R&D alliance agreements and collaborations between Oncoceutics and leading cancer research institutions, including The University of Texas MD Anderson Cancer Center, the NIH/NCI, Harvard and the Fox Chase Cancer Center. The company has established a robust intellectual property position, including several issued patents.
